AUSTIN, Texas—Solomon Moshkevich, president of clinical diagnostics at Natera, Inc. (NASDAQ: ), recently sold a significant portion of its stake in the company. The sale comes as Natera’s stock has shown incredible strength, returning 159% over the past year, and the company has achieved a market capitalization of $22.12 billion. According to a filing with the Securities and Exchange Commission, Moshkevich sold a total of 24,861 shares of Natera’s common stock on Jan. 22, 2025, netting approximately $4.1 million. These transactions occurred at prices ranging from $164.95 to $171.95 per share.
Following this sale, Moshkevich retains ownership of 140,684 shares in the company. According to the filing, the sale was made to satisfy withholding tax obligations related to the acquisition of restricted stock units, in accordance with a pre-determined trading plan. InvestingPro analysis shows that Natera maintains a strong financial position with a ‘GOOD’ health rating and strong liquidity, as evidenced by a current ratio of 4.39. For deeper insight into insider trading patterns and comprehensive financial analysis, investors can access the detailed Pro Research Report, available exclusively on InvestingPro.
In other recent news, Natera Inc . making waves in the industry. Barclays ( LON: ) recently upgraded the company’s stock to Overweight with a $200 target, citing its expansion into new markets and impressive revenue growth of nearly 55% over the past twelve months. Analyst Luke Sergott noted Natera’s evolution from its original focus on non-NGS-based NIPT to becoming a leading player in the NIPT market and its expansion into oncology and NGS-based organ health testing.
Natera also expanded its patent infringement lawsuit against NeoGenomics (NASDAQ: ) to include the RaDaR test. Despite the failure of the false advertising lawsuit Guardian of health (NASDAQ: ), Natera plans to ask the court to overturn the ruling. Additionally, the agreement with dr. Rabinowitz, executive chairman, was replaced so that he would continue in his role under certain conditions.
TD Cowen reiterated a Buy rating on Nater stock, raising its price target to $195 from $175, reflecting confidence in the company’s future performance. Similarly, Baird and Jefferies also maintained their favorable ratings on Natera’s stock and raised their price targets.
Finally, Natera reported record third-quarter revenue of $439.8 million, a 64% year-over-year increase, and performed 137,000 oncology tests. These recent developments provide investors with insight into Natera’s current status and future prospects.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
